tetano
Editor, Senior Moderator
Med Clin (Barc)
. 2021 Jun 17;S0025-7753(21)00320-1.
doi: 10.1016/j.medcli.2021.05.014. Online ahead of print.
Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study
[Article in English, Spanish]
Jian Wang[SUP] 1 [/SUP], Li Zhu[SUP] 2 [/SUP], Longgen Liu[SUP] 3 [/SUP], Xuebing Yan[SUP] 4 [/SUP], Leyang Xue[SUP] 5 [/SUP], Songping Huang[SUP] 6 [/SUP], Biao Zhang[SUP] 7 [/SUP], Tianmin Xu[SUP] 3 [/SUP], Fang Ji[SUP] 4 [/SUP], Chunyang Li[SUP] 4 [/SUP], Fang Ming[SUP] 6 [/SUP], Yun Zhao[SUP] 8 [/SUP], Juan Cheng[SUP] 9 [/SUP], Kang Chen[SUP] 10 [/SUP], Xiang-An Zhao[SUP] 11 [/SUP], Dawen Sang[SUP] 9 [/SUP], Xinying Guan[SUP] 12 [/SUP], Xiaobing Chen[SUP] 13 [/SUP], Xiaomin Yan[SUP] 1 [/SUP], Zhaoping Zhang[SUP] 1 [/SUP], Jiacheng Liu[SUP] 14 [/SUP], Rui Huang[SUP] 15 [/SUP], Chuanwu Zhu[SUP] 16 [/SUP], Chao Wu[SUP] 17 [/SUP]
Affiliations
Abstract
Background: Few studies have investigated the impacts of metabolic syndrome (MS) on coronavirus disease 2019 (COVID-19). We described the clinical features and prognosis of confirmed COVID-19 patients with MS during hospitalization and after discharge.
Methods: Two hundred and thirty-three COVID-19 patients from the hospitals in 8 cities of Jiangsu, China were retrospectively included. Clinical characteristics of COVID-19 patients were described and risk factors of severe illness were analyzed by logistic regression analysis.
Results: Forty-five (19.3%) of 233 COVID-19 patients had MS. The median age of COVID-19 patients with MS was significantly higher than non-MS patients (53.0 years vs. 46.0 years, P=0.004). There were no significant differences of clinical symptoms, abnormal chest CT images, and treatment drugs between two groups. More patients with MS had severe illness (33.3% vs. 6.4%, P<0.001) and critical illness (4.4% vs. 0.5%, P=0.037) than non-MS patients. The proportions of respiratory failure and acute respiratory distress syndrome in MS patients were also higher than non-MS patients during hospitalization. Multivariate analysis showed that concurrent MS (odds ratio [OR] 7.668, 95% confidence interval [CI] 3.062-19.201, P<0.001) and lymphopenia (OR 3.315, 95% CI 1.306-8.411, P=0.012) were independent risk factors of severe illness of COVID-19. At a median follow-up of 28 days after discharge, bilateral pneumonia was found in 95.2% of MS patients, while only 54.7% of non-MS patients presented bilateral pneumonia.
Conclusions: 19.3% of COVID-19 patients had MS in our study. COVID-19 patients with MS are more likely to develop severe complications and have worse prognosis. More attention should be paid to COVID-19 patients with MS.
Keywords: Coronavirus disease 2019; Enfermedad por coronavirus 2019; Metabolic syndrome; Prognosis; Pronóstico; Síndrome metabólico.
. 2021 Jun 17;S0025-7753(21)00320-1.
doi: 10.1016/j.medcli.2021.05.014. Online ahead of print.
Clinical features and prognosis of COVID-19 patients with metabolic syndrome: A multicenter, retrospective study
[Article in English, Spanish]
Jian Wang[SUP] 1 [/SUP], Li Zhu[SUP] 2 [/SUP], Longgen Liu[SUP] 3 [/SUP], Xuebing Yan[SUP] 4 [/SUP], Leyang Xue[SUP] 5 [/SUP], Songping Huang[SUP] 6 [/SUP], Biao Zhang[SUP] 7 [/SUP], Tianmin Xu[SUP] 3 [/SUP], Fang Ji[SUP] 4 [/SUP], Chunyang Li[SUP] 4 [/SUP], Fang Ming[SUP] 6 [/SUP], Yun Zhao[SUP] 8 [/SUP], Juan Cheng[SUP] 9 [/SUP], Kang Chen[SUP] 10 [/SUP], Xiang-An Zhao[SUP] 11 [/SUP], Dawen Sang[SUP] 9 [/SUP], Xinying Guan[SUP] 12 [/SUP], Xiaobing Chen[SUP] 13 [/SUP], Xiaomin Yan[SUP] 1 [/SUP], Zhaoping Zhang[SUP] 1 [/SUP], Jiacheng Liu[SUP] 14 [/SUP], Rui Huang[SUP] 15 [/SUP], Chuanwu Zhu[SUP] 16 [/SUP], Chao Wu[SUP] 17 [/SUP]
Affiliations
- PMID: 34243955
- DOI: 10.1016/j.medcli.2021.05.014
Abstract
Background: Few studies have investigated the impacts of metabolic syndrome (MS) on coronavirus disease 2019 (COVID-19). We described the clinical features and prognosis of confirmed COVID-19 patients with MS during hospitalization and after discharge.
Methods: Two hundred and thirty-three COVID-19 patients from the hospitals in 8 cities of Jiangsu, China were retrospectively included. Clinical characteristics of COVID-19 patients were described and risk factors of severe illness were analyzed by logistic regression analysis.
Results: Forty-five (19.3%) of 233 COVID-19 patients had MS. The median age of COVID-19 patients with MS was significantly higher than non-MS patients (53.0 years vs. 46.0 years, P=0.004). There were no significant differences of clinical symptoms, abnormal chest CT images, and treatment drugs between two groups. More patients with MS had severe illness (33.3% vs. 6.4%, P<0.001) and critical illness (4.4% vs. 0.5%, P=0.037) than non-MS patients. The proportions of respiratory failure and acute respiratory distress syndrome in MS patients were also higher than non-MS patients during hospitalization. Multivariate analysis showed that concurrent MS (odds ratio [OR] 7.668, 95% confidence interval [CI] 3.062-19.201, P<0.001) and lymphopenia (OR 3.315, 95% CI 1.306-8.411, P=0.012) were independent risk factors of severe illness of COVID-19. At a median follow-up of 28 days after discharge, bilateral pneumonia was found in 95.2% of MS patients, while only 54.7% of non-MS patients presented bilateral pneumonia.
Conclusions: 19.3% of COVID-19 patients had MS in our study. COVID-19 patients with MS are more likely to develop severe complications and have worse prognosis. More attention should be paid to COVID-19 patients with MS.
Keywords: Coronavirus disease 2019; Enfermedad por coronavirus 2019; Metabolic syndrome; Prognosis; Pronóstico; Síndrome metabólico.